Chemomab Therapeutics Ltd.
CMMB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $34 | $0 | $0 |
| Gross Profit | $0 | -$34 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $960 | $1,287 | $2,493 | $2,411 |
| G&A Expenses | $884 | $975 | $994 | $802 |
| SG&A Expenses | $884 | $975 | $994 | $802 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1,844 | $2,262 | $3,487 | $3,213 |
| Operating Income | -$1,844 | -$2,262 | -$3,487 | -$3,213 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $102 | $205 | $164 | $250 |
| Pre-Tax Income | -$1,742 | -$2,057 | -$3,323 | -$2,963 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1,742 | -$2,057 | -$3,323 | -$2,963 |
| % Margin | – | – | – | – |
| EPS | -0.28 | -0.36 | -0.58 | -0.63 |
| % Growth | 22.2% | 37.9% | 7.9% | – |
| EPS Diluted | -0.28 | -0.36 | -0.58 | -0.63 |
| Weighted Avg Shares Out | 6,179 | 5,794 | 5,702 | 4,714 |
| Weighted Avg Shares Out Dil | 6,179 | 5,794 | 5,702 | 4,714 |
| Supplemental Information | – | – | – | – |
| Interest Income | $102 | $209 | $163 | $252 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $13 | $34 | $13 | $6 |
| EBITDA | -$1,844 | -$2,066 | -$3,474 | -$3,207 |
| % Margin | – | – | – | – |